Skip to main content

Advertisement

SpringerLink
Log in

Acute Effects of Calcitonin Nasal Spray on Serum C-telopeptide of Type 1 Collagen (CTx) Levels in Elderly Osteopenic Women with Increased Bone Turnover

  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Abstract

Salmon calcitonin is a potent inhibitor of osteoclastic activity. The effect of calcitonin in elderly women with high bone turnover at higher risk of developing osteoporosis has not been studied. To investigate acute effects of calcitonin treatment on bone resorption markers in elderly women, we conducted a randomized trial in women >65 years of age with high bone turnover assessed as urinary N-telopeptide of type-I collagen (NTx) levels 1 SD higher than mean premenopausal levels, which was irrespective of bone density. A total of 98 elderly women were randomly assigned to receive either 200 IU calcitonin nasal spray (n = 75) with calcium (500 mg) and vitamin D (200 IU) or calcium and vitamin D (n = 23) alone for 6 months. Blood and urine samples were collected at 0, 2, 4, and 6 months and analyzed for urinary NTx and serum C-telopeptide of type-1 collagen (CTx). At baseline, mean age was 72.1 ± 4.7 (mean ± SD) in the calcitonin group and 72.2 ± 6 years in the control group. The spine and total hip BMD, serum PTH levels and urinary calcium/creatinine ratios were similar in both groups. Mean BMD was in the osteopenic range in both groups. Calcitonin treatment resulted in significant decreases in serum CTx levels, 2, 4 and 6 months after treatment as compared to baseline, and after 4 and 6 months as compared to controls. A maximum decrease from baseline of 33% was seen at 6 months. The urinary resorption marker, urine NTx, showed a significant decrease in the calcitonin group when compared to baseline only at the 6-month time point. Analysis of least significance change (LSC) showed that 70% of calcitonin patients were categorized as responders using serum CTx after 6 months of treatment. We conclude that 200 IU calcitonin effectively decreases bone resorption within 60 days of therapy, thus preventing further bone loss in elderly women who are at a high risk of developing osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. CH Chesnut S Silverman K Andriano et al. (2000) ArticleTitleA randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. PROOF Study Group Am J Med 109 267–276 Occurrence Handle10.1016/S0002-9343(00)00490-3 Occurrence Handle1:CAS:528:DC%2BD3cXms1Wku70%3D Occurrence Handle10996576

    Article  CAS  PubMed  Google Scholar 

  2. JJ Body (2002) ArticleTitleCalcitonin for the long-term prevention and treatment of postmenopausal osteoporosis Bone 30 75S–79S Occurrence Handle10.1016/S8756-3282(02)00715-9 Occurrence Handle1:CAS:528:DC%2BD38Xjtl2lurw%3D Occurrence Handle12008163

    Article  CAS  PubMed  Google Scholar 

  3. A Cranney P Tugwell N Zytaruk et al. (2002) ArticleTitleMeta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis Endo Rev 23 540–551 Occurrence Handle10.1210/er.2001-6002 Occurrence Handle1:CAS:528:DC%2BD38Xnt1Wiu7c%3D

    Article  CAS  Google Scholar 

  4. TM Huusko P Karppi H Kautiainen et al. (2002) ArticleTitleRandomized, double-blind, clinically controlled trial of intranasal calcitonin treatment in patients with hip fracture Calcif Tissue Int 71 478–484 Occurrence Handle10.1007/s00223-001-2111-x Occurrence Handle1:CAS:528:DC%2BD3sXjt1antQ%3D%3D Occurrence Handle12370798

    Article  CAS  PubMed  Google Scholar 

  5. GP Trovas GP Lyritis A Galanos et al. (2002) ArticleTitleA randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers J Bone Miner Res 17 521–527 Occurrence Handle1:CAS:528:DC%2BD38XitVKhtLw%3D Occurrence Handle11874243

    CAS  PubMed  Google Scholar 

  6. M Azria (1989) The calcitonins: physiology and pharmacology Karger New York

    Google Scholar 

  7. B Baron A Vignery (1981) ArticleTitleBehavior of osteoclasts during rapid change in their number induced by high doses of parathyroid hormone or calcitonin in intact rats Metab Bone Dis Rel Res 2 339–346 Occurrence Handle10.1016/0221-8747(81)90020-5 Occurrence Handle1:CAS:528:DyaL3MXhsFSks70%3D

    Article  CAS  Google Scholar 

  8. DM Kallio PR Garant C Minkin (1972) ArticleTitleUltrastructural effects of calcitonin on osteoclasts in tissue culture J Ultrastruct Res 39 205–216 Occurrence Handle1:CAS:528:DyaE38XkvVekurk%3D Occurrence Handle4337397

    CAS  PubMed  Google Scholar 

  9. DA Hanson MA Weis AM Bollen et al. (1992) ArticleTitleA specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine J Bone Miner Res 7 IssueID11 1251–1258 Occurrence Handle1:CAS:528:DyaK3sXns1CrtQ%3D%3D Occurrence Handle1466251

    CAS  PubMed  Google Scholar 

  10. C Rosenquist C Fledelius S Christgau BJ Pendersen M Bonde P Qvist et al. (1998) ArticleTitleSerum crosslaps one step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen Clin Chem 44 IssueID11 2281–2289 Occurrence Handle1:CAS:528:DyaK1cXnt1Olt74%3D Occurrence Handle9799755

    CAS  PubMed  Google Scholar 

  11. A Braga_de_Castro_Machado R Hannon R Eastell (1999) ArticleTitleMonitoring alendronate therapy for osteoporosis J Bone Miner Res 14 602–608 Occurrence Handle1:STN:280:DyaK1M3ltVynsw%3D%3D Occurrence Handle10234582

    CAS  PubMed  Google Scholar 

  12. AM Parfitt (2002) ArticleTitleHigh bone turnover is intrinsically harmful: two paths to a similar conclusion. The Parfitt view J Bone Miner Res 17 IssueID8 1558–1560 Occurrence Handle12162510

    PubMed  Google Scholar 

  13. BL Riggs LJ Melton (2002) ArticleTitleBone turnover matters: the raloxifene treatment paradox of dramatic decrease in vertebral fractures without commensurate increase in bone density J Bone Miner Res 17 11–14 Occurrence Handle11771656

    PubMed  Google Scholar 

  14. SR Cummings DM Black TM Vogt (1996) ArticleTitleChanges in BMD substantially underestimates the anti-fracture effect of alendronate and other antiresorptive drugs J Bone Miner Res 11 IssueIDsuppl 1 S102

    Google Scholar 

  15. PLA Daele ParticleVan J Seibel H Burger et al. (1996) ArticleTitleCase-control analysis of bone resorption markers, disability, hip fracture risk: The Rotterdam study BMJ 312 482–483 Occurrence Handle8597681

    PubMed  Google Scholar 

  16. SR Cummings DB Karpf F Harris et al. (2002) ArticleTitleImprovement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs Am J Med 112 281–289 Occurrence Handle10.1016/S0002-9343(01)01124-X Occurrence Handle1:CAS:528:DC%2BD38XhvVWkurk%3D Occurrence Handle11893367

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. JLP VA Medical Center, Musculoskeletal Disease Center, Loma Linda, CA 92357, USA

    Apurva K. Srivastava, Cesar Libanati, Omar Hohmann & David J. Baylink

  2. Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ 07936, USA

    Audrey Kriegman

Authors
  1. Apurva K. Srivastava
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cesar Libanati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Omar Hohmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Audrey Kriegman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David J. Baylink
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David J. Baylink.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Srivastava, A.K., Libanati, C., Hohmann, O. et al. Acute Effects of Calcitonin Nasal Spray on Serum C-telopeptide of Type 1 Collagen (CTx) Levels in Elderly Osteopenic Women with Increased Bone Turnover. Calcif Tissue Int 75, 477–481 (2004). https://doi.org/10.1007/s00223-004-0036-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-004-0036-x

Keywords

Search

Navigation